文献速递白血病

预测初治伊马替尼治疗慢性髓性白血病慢性期患者分子学反应的评分系统

[A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

本研究纳入1364例接受一线伊马替尼治疗的初发CML-CP成人患者,按2∶1随机分为训练集909例和验证集455例,采用Fine-Gray模型建立基于性别、WBC、HGB和ELTS评分的MMR及MR4预测评分系统,两模型时间依赖性AUROC范围分别为0.70~0.84和0.64~0.81。

要点

  • MMR模型:男性、ELTS中危、低HGB(<110 g/L)各1分,ELTS高危、高WBC(≥130×10⁹/L)各2分。
  • MR4模型:男性1分,ELTS中危与低HGB各2分,高WBC(≥120×10⁹/L)3分,ELTS高危4分。
  • 两模型在训练集和验证集中不同危险组累积MMR、MR4获得率差异均P<0.001。

核心结论

  • 联合性别、初诊时WBC、HGB水平和ELTS评分建立了一线伊马替尼治疗CML-CP患者获得MMR及MR4的临床预测模型,该模型区分度、精确度良好,可帮助指导一线治疗药物的选择。

研究设计与样本

  • 收集2006年1月至2022年3月在北京大学人民医院接受伊马替尼一线治疗的成人CML-CP连续病例,按2∶1比例随机分为训练集和验证集。
  • 训练集采用竞争风险模型(Fine-Gray模型)探索MMR及MR4的独立影响因素并建立临床预测模型,验证集完成内部验证。
  • 采用时间依赖性受试者工作特征曲线下面积(AUROC)评价预测模型区分度。

主要发现

  • 共纳入1364例患者,训练集909例,验证集455例。
  • 训练集多因素分析显示男性、ELTS评分中/高危、初诊时高WBC、低HGB水平与较低的MMR与MR4累积获得率显著相关。
  • 根据预测模型将患者分为MMR与MR4低、中、高危组,不同危险组累积MMR、MR4获得率差异均具有统计学意义(P值均<0.001)。
  • 训练集及验证集中,MMR和MR4预测模型的时间依赖性AUROC范围分别为0.70~0.84和0.64~0.81。

关键数值与推荐

  • MMR临床预测模型:男性、ELTS评分中危及低HGB水平(<110 g/L)赋1分,ELTS评分高危、初诊时高WBC(≥130×10⁹/L)赋2分。
  • MR4临床预测模型:男性赋1分,ELTS评分中危与低HGB水平各赋2分,初诊时高WBC(≥120×10⁹/L)赋3分,ELTS评分高危赋4分。

临床怎么用

  • 该模型可帮助指导一线治疗药物的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To develop a scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase (CML-CP) receiving initial imatinib therapy. Methods: Data from consecutive adults with newly diagnosed CML-CP treated by initial imatinib was interrogated and subjects were distributed randomly into training and validation cohort, in a ratio of 2∶1. Fine-gray models were applied in the training cohort to identify co-variates of predictive value for major molecular response (MMR) and MR4. A predictive system was built using significant co-variates. The predictive system was then tested in the validation cohort and the area under the receiver-operator characteristic curve (AUROC) was used to estimate accuracy of the predictive system. Results: 1 364 CML-CP subjects receiving initial imatinib were included in this study. Subjects were distributed randomly into training cohort (n=909) and validation cohort (n=455) . In the training cohort, the male gender, European Treatment and Outcome Study for CML (EUTOS) Long-Term Survival (ELTS) intermediate-risk, ELTS high-risk, high WBC (≥130×10(9)/L or 120×10(9)/L, MMR or MR4) and low HGB (<110 g/L) at diagnosis were significantly related with poor molecular responses and were given points based on their regression coefficients. For MMR, male gender, ELTS intermediate-risk and low HGB (<110 g/L) were given 1 point; ELTS high-risk and high WBC (≥130×10(9)/L) , 2 points. For MR4, male gender was given 1 point; ELTS intermediate-risk and low HGB (<110 g/L) were given 2 points; high WBC (≥120×10(9)/L) , 3 points; ELTS high-risk, 4 points. We divided all subjects into 3 risk subgroups according to the predictive system above. Cumulative incidence of achieving MMR and MR4 in 3 risk subgroups was significantly different in both training and validation cohort (all P values <0.001) . In the training and validation cohorts, the time-dependent AUROC ranges of MMR and MR4 predictive systems were 0.70-0.84 and 0.64-0.81, respectively. Conclusions: A scoring system combining gender, WBC, HGB level and ELTS risk was built to predict MMR and MR4 in CML-CP patients receiving initial imatinib therapy. This system had good discrimination and accuracy, which could help phsicians optimize the selsction of initial TKI-therapy. 目的: 建立一线伊马替尼治疗的初发慢性髓性白血病慢性期(CML-CP)患者获得分子学反应的临床预测模型。 方法: 收集2006年1月至2022年3月在北京大学人民医院接受伊马替尼一线治疗的成人CML-CP连续病例,将患者按2∶1比例随机分为训练集和验证集。在训练集中,采用竞争风险模型探索主要分子学反应(MMR)及分子学反应4(MR4)的独立影响因素,建立临床预测模型,在验证集中完成内部验证。采用时间依赖性受试者工作特征曲线下面积(AUROC)评价预测模型区分度。 结果: 共纳入1 364例患者,训练集909例,验证集455例。在训练集中,多因素分析显示男性、ELTS评分中/高危、初诊时高WBC、低HGB水平与较低的MMR与MR4累积获得率显著相关。根据回归系数建立MMR临床预测模型:男性、ELTS评分中危及低HGB水平(<110 g/L)赋1分,ELTS评分高危、初诊时高WBC(≥130×10(9)/L)赋2分;建立MR4临床预测模型:男性赋1分,ELTS评分中危与低HGB水平各赋2分,初诊时高WBC(≥120×10(9)/L)赋3分,ELTS评分高危赋4分。根据上述预测模型,将患者分为MMR与MR4低、中、高危组,不同危险组累积MMR、MR4获得率差异均具有统计学意义(P值均<0.001)。在训练集及验证集中,MMR和MR4预测模型的时间依赖性AUROC范围分别为0.70~0.84和0.64~0.81。 结论: 通过联合性别、初诊时WBC、HGB水平和ELTS评分建立了一线伊马替尼治疗的CML-CP患者获得MMR及MR4的临床预测模型,该模型区分度、精确度良好,可帮助指导一线治疗药物的选择。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li ZY, Zhang MY, Zhang XS, et al. [A scoring system to predict molecular responses in patients with chronic myeloid leukemia in the chronic phase receiving initial imatinib therapy]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 36948863. doi:10.3760/cma.j.issn.0253-2727.2023.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。